Symptomatic Patients With Myelofibrosis Treated Post-JAK Inhibition

home / case-based-roundtable-series / symptomatic-patients-with-myelofibrosis-treated-post-jak-inhibition

This roundtable series explores options for anemic patients with myelofibrosis after they have received a JAK inhibitor, as discussed by key opinion leaders and participants at virtual live events.

Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis

Momelotinib Impacts Treatment Methods for Anemia in Myelofibrosis

Aaron T. Gerds, MD, MS
September 15th 2023

Results of the phase 3 MOMENTUM study showed that the JAK1/JAK2 inhibitor momelotinib can provide treatment for the patient’s disease and also their anemia.